{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:24:04Z","timestamp":1786994644491,"version":"build-2736575974"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["No.2022JJ80036"],"award-info":[{"award-number":["No.2022JJ80036"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific research project of Hunan health Commission","award":["No.20200202"],"award-info":[{"award-number":["No.20200202"]}]},{"name":"Clinical pharmacy research project of Hunan Medical Association","award":["No.HMA202001006"],"award-info":[{"award-number":["No.HMA202001006"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Nirmatrelvir\/Ritonavir, acting as an effective agent against COVID-19, has achieved considerable results in clinical studies in terms of drug efficacy. However, there is little research about its medication safety. Based on the FDA adverse event reporting system (FAERS) database, this study aims to mine the adverse reaction signals of the latest major recommended drug Nirmatrelvir\/Ritonavir for the antiviral treatment of COVID-19, so as to provide a basis for safe and rational drug use. The reporting odds ratio (ROR) was used to explore the adverse event report data of all COVID-19 emergency use authorization (EUA) products in the FAERS database with the deadline of third quarter of 2023. In the analysis, 135427 adverse drug event (ADE) reports were found, and 35250 ADEs were reported with Nirmatrelvir\/Ritonavir as the primary suspected drug, which was involved in multiple system. There was a high signal intensity of dysgeusia (ROR = 72.98), diarrhea (ROR = 3.03) and headache (ROR = 1.25), which was compatible with the adverse reactions recorded in the manual for Nirmatrelvir\/Ritonavir. In addition, it was suggested that Nirmatrelvir\/Ritonavir might cause pale-colored stools (ROR = 45.53), chromaturia (ROR = 3.07), yellow skin (ROR = 3.62), tongue coating (ROR = 35.55) and other new adverse reactions (not included in the instructions manual for Nirmatrelvir\/Ritonavir). The ADEs of Nirmatrelvir\/Ritonavir that are not in the instructions and are highly relevant in the real world are supplemented, prompting clinical attention to the ADEs of the drug, and providing a theoretical basis for the safe and effective application of the drug.<\/jats:p>","DOI":"10.1371\/journal.pone.0316573","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T18:47:23Z","timestamp":1735670843000},"page":"e0316573","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Data mining of adverse drug event signals with Nirmatrelvir\/Ritonavir from FAERS"],"prefix":"10.1371","volume":"19","author":[{"given":"Ji","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanyu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gefei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0946-9097","authenticated-orcid":true,"given":"Shiqiong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"issue":"1","key":"pone.0316573.ref001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/d41573-021-00202-8","article-title":"A tale of two antiviral targets\u2014and the COVID-19 drugs that bind them","volume":"21","author":"M. Cully","year":"2022","journal-title":"Nature reviews Drug discovery"},{"issue":"4","key":"pone.0316573.ref002","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cpt.1866","article-title":"Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System","volume":"108","author":"J Sun","year":"2020","journal-title":"Clinical pharmacology and therapeutics"},{"issue":"1","key":"pone.0316573.ref003","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/FTD.0000000000000838","article-title":"Plasma Concentrations and Safety of Lopinavir\/Ritonavir in COVID-19 Patients","volume":"43","author":"L Chouchana","year":"2021","journal-title":"Therapeutic drug monitoring"},{"issue":"10223","key":"pone.0316573.ref004","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"C Huang","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"9","key":"pone.0316573.ref005","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/s41591-022-01911-2","article-title":"Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa","volume":"28","author":"H Tegally","year":"2022","journal-title":"Nature medicine"},{"issue":"3","key":"pone.0316573.ref006","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41422-022-00618-w","article-title":"SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination","volume":"32","author":"P Li","year":"2022","journal-title":"Cell Res"},{"issue":"5","key":"pone.0316573.ref007","first-page":"1766","article-title":"In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery","volume":"94","author":"Z Wang","year":"2022"},{"issue":"4","key":"pone.0316573.ref008","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.ajkd.2022.01.001","article-title":"Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection","volume":"79","author":"S Fishbane","year":"2022","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"issue":"3","key":"pone.0316573.ref009","doi-asserted-by":"crossref","first-page":"236","DOI":"10.37201\/req\/002.2022","article-title":"Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination","volume":"35","author":"J Reina","year":"2022","journal-title":"Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia"},{"issue":"5","key":"pone.0316573.ref010","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir Plus Ritonavir: First Approval","volume":"82","author":"YN Lamb","year":"2022","journal-title":"Drugs"},{"key":"pone.0316573.ref011","first-page":"o1037","article-title":"Covid-19: What is the evidence for the antiviral Paxlovid?","volume":"377","author":"A. Extance","year":"2022","journal-title":"BMJ (Clinical research ed)"},{"key":"pone.0316573.ref012","first-page":"n2713","article-title":"Covid-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"E. Mahase","year":"2021","journal-title":"BMJ (Clinical research ed)"},{"key":"pone.0316573.ref013","unstructured":"An official website of the United States government. Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19."},{"issue":"1","key":"pone.0316573.ref014","first-page":"516","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis","volume":"54","author":"W Wen","year":"2022"},{"issue":"15","key":"pone.0316573.ref015","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19","volume":"386","author":"J Hammond","year":"2022","journal-title":"The New England journal of medicine"},{"issue":"7906","key":"pone.0316573.ref016","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/d41586-022-00919-5","article-title":"African clinical trial denied access to key COVID drug Paxlovid","volume":"604","author":"H Ledford","year":"2022","journal-title":"Nature"},{"key":"pone.0316573.ref017","doi-asserted-by":"crossref","first-page":"160026","DOI":"10.1038\/sdata.2016.26","article-title":"A curated and standardized adverse drug event resource to accelerate drug safety research","volume":"3","author":"JM Banda","year":"2016","journal-title":"Scientific data"},{"issue":"12","key":"pone.0316573.ref018","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40264-013-0116-9","article-title":"Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database","volume":"36","author":"AD Brinker","year":"2013","journal-title":"Drug safety"},{"issue":"2","key":"pone.0316573.ref019","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"JS Almenoff","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"pone.0316573.ref020","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.ekir.2024.07.006","article-title":"Exploring Novel Adverse Events of Nefecon","volume":"9","author":"J Wang","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"4","key":"pone.0316573.ref021","doi-asserted-by":"crossref","first-page":"e14522","DOI":"10.1111\/cns.14522","article-title":"Psychiatric disorders associated with PCSK9 inhibitors: A real-world, pharmacovigilance study","volume":"30","author":"Z Deng","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"pone.0316573.ref022","unstructured":"Signal management. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/humanregulatory-overview\/post-authorisation\/pharmacovigilancepost-authorisation\/signal-management#designated-medicalevents-10341."},{"key":"pone.0316573.ref023","unstructured":"EudraVigilance system overview. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance\/eudravigilance-system-overview."},{"key":"pone.0316573.ref024","unstructured":"Pfzer Canada ULC. Paxlovid: Canadian product monograph. 2022. https:\/\/covid-vaccine.canada.ca\/. Accessed 21 Feb 2022."},{"key":"pone.0316573.ref025","doi-asserted-by":"crossref","first-page":"e00975","DOI":"10.1016\/j.idcr.2020.e00975","article-title":"Case report of familial COVID-19 cluster associated with High prevalence of anosmia, ageusia, and gastrointestinal symptoms","volume":"22","author":"BE Ho","year":"2020","journal-title":"IDCases"},{"issue":"2","key":"pone.0316573.ref026","first-page":"307","article-title":"Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence","volume":"278","author":"E Mehraeen","year":"2021"},{"issue":"4","key":"pone.0316573.ref027","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0194599820934380","article-title":"Olfactory and Oral Manifestations of COVID-19: Sex-Related Symptoms-A Potential Pathway to Early Diagnosis","volume":"163","author":"A Biadsee","year":"2020","journal-title":"Otolaryngology\u2014head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery"},{"issue":"21","key":"pone.0316573.ref028","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"J Shang","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"pone.0316573.ref029","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/s41591-020-0968-3","article-title":"Extrapulmonary manifestations of COVID-19","volume":"26","author":"A Gupta","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"pone.0316573.ref030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41368-020-0074-x","article-title":"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa","volume":"12","author":"H Xu","year":"2020","journal-title":"Int J Oral Sci"},{"issue":"5","key":"pone.0316573.ref031","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/dmd.121.000801","article-title":"Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans","volume":"50","author":"H Eng","year":"2022","journal-title":"Drug Metab Dispos"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T18:47:38Z","timestamp":1735670858000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316573"}},"subtitle":[],"editor":[{"given":"Jingyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0316573","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]}}}